ncRNA basic information ncRNA ID: MI0000079 ncRNA Database: miRBase ncRNA Name: miR-23a ncRNA Type: miRNA ncRNA Expression: down-regulated ncRNA Method: RT-qPCR ncRNA Target Gene: PTEN ncRNA Pathway: PTEN/PI3K/Akt pathway Evidence (ncRNA-drug): validated

drug basic information Drug ID: DB00530 (APRD00951) Drug Name: Erlotinib Drug Method: In the present study, we isolated cancer stem cells (CSCs) from the PC9 NSCLC cell line. We then observed that the PC9 CSCs showed significant resistance to erlotinib compared with the PC9 non-CSCs. Erlotinib failed to suppress the phosphorylation of PI3K and AKT in PC9 CSCs, although the EGFR was inhibited sufficiently. Mechanically, we observed aberrant upregulation of microRNA-23a (miR-23a) and downregulation of PTEN in PC9 CSCs compared to PC9 non-CSCs. Luciferase reporter assays proved that PTEN was the target of miR-23a in PC9 CSCs. Furthermore, knockdown of miR-23a enhanced the antitumor effect of erlotinib by increasing the expression of PTEN. In addition, transfection with miR-23a inhibitors promoted the erlotinib-dependent inhibition of PI3K/AKT pathway, thus, suppressing the proliferation and inducing apoptosis in PC9 CSCs. These results propose that upregulation of miR-23a is a potential mechanism associated with resistance to EGFR-TKIs in lung cancer stem cells. Inhibition of miR-23a serves as a novel therapeutic strategy to eliminate the EGFR-TKIs resistance of lung cancer stem cells. Drug Response: sensitive

Cancer basic information Cancer: lung cancer Tissue/Cell: cell line (PC9)

Other information Title: Inhibition of miR-23a increases the sensitivity of lung cancer stem cells to erlotinib through PTEN/PI3K/Akt pathway. Journal: Oncol Rep Published: 2017 PubMed ID: 28901474